APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antibody Drug Conjugates (ADCs)

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Antibody Drug Conjugates (ADCs) Market Analysis and Forecast 2026-2032

20 December 2025199 pages

Choose your research edition.

Industry ResearchAntibody Drug Conjugates (ADCs) Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Antibody Drug Conjugates (ADCs) Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Antibody Drug Conjugates (ADCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antibody Drug Conjugates (ADCs) Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Antibody Drug Conjugates (ADCs) Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Antibody Drug Conjugates (ADCs) market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Antibody Drug Conjugates (ADCs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Antibody Drug Conjugates (ADCs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Antibody Drug Conjugates (ADCs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Antibody Drug Conjugates (ADCs) is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Antibody Drug Conjugates (ADCs) include AbGenomics, ADC Therapeutics, Astellas Pharma, Genmab, Kairos Therapeutics, Seattle Genetics, Takeda Pharmaceuticals, AbbVie and Bayer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Antibody Drug Conjugates (ADCs), market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Antibody Drug Conjugates (ADCs), also provides the revenue of main regions and countries. Of the upcoming market potential for Antibody Drug Conjugates (ADCs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Antibody Drug Conjugates (ADCs) revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Antibody Drug Conjugates (ADCs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Antibody Drug Conjugates (ADCs) revenue, projected growth trends, production technology, application and end-user industry.

Antibody Drug Conjugates (ADCs) Segment by Company

AbGenomics

ADC Therapeutics

Astellas Pharma

Genmab

Kairos Therapeutics

Seattle Genetics

Takeda Pharmaceuticals

AbbVie

Bayer

Pfizer

Roche

Novartis

Antibody Drug Conjugates (ADCs) Segment by Type

Seattle Genetics Technology

Immunomedics Technology

ImmunoGen Technology

Antibody Drug Conjugates (ADCs) Segment by Application

Hospital

Clinics

Others

Antibody Drug Conjugates (ADCs) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Drug Conjugates (ADCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antibody Drug Conjugates (ADCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Drug Conjugates (ADCs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Antibody Drug Conjugates (ADCs) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Antibody Drug Conjugates (ADCs) company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Antibody Drug Conjugates (ADCs) revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Seattle Genetics Technology Major Player Table 3. Immunomedics Technology Major Player Table 4. ImmunoGen Technology Major Player Table 5. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Hospital Major Player Table 7. Clinics Major Player Table 8. Others Major Player Table 9. Antibody Drug Conjugates (ADCs) Industry Trends Table 10. Antibody Drug Conjugates (ADCs) Industry Drivers Table 11. Antibody Drug Conjugates (ADCs) Industry Opportunities and Challenges Table 12. Antibody Drug Conjugates (ADCs) Industry Restraints Table 13. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Antibody Drug Conjugates (ADCs) Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Antibody Drug Conjugates (ADCs) Market Share by Region (2021-2026) Table 16. Global Antibody Drug Conjugates (ADCs) Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Antibody Drug Conjugates (ADCs) Market Share by Region (2027-2032) Table 18. Global Antibody Drug Conjugates (ADCs) Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Players (2021-2026) Table 20. Global Antibody Drug Conjugates (ADCs) Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Antibody Drug Conjugates (ADCs) Key Players Headquarters & Area Served Table 22. Global Antibody Drug Conjugates (ADCs) Players, Product Type & Application Table 23. Global Antibody Drug Conjugates (ADCs) Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Antibody Drug Conjugates (ADCs) by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Antibody Drug Conjugates (ADCs) Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Antibody Drug Conjugates (ADCs) Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2021-2026) Table 30. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2027-2032) Table 31. Global Antibody Drug Conjugates (ADCs) Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Antibody Drug Conjugates (ADCs) Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2021-2026) Table 35. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2027-2032) Table 36. AbGenomics Company Information Table 37. AbGenomics Business Overview Table 38. AbGenomics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. AbGenomics Antibody Drug Conjugates (ADCs) Product Portfolio Table 40. AbGenomics Recent Development Table 41. ADC Therapeutics Company Information Table 42. ADC Therapeutics Business Overview Table 43. ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. ADC Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio Table 45. ADC Therapeutics Recent Development Table 46. Astellas Pharma Company Information Table 47. Astellas Pharma Business Overview Table 48. Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Astellas Pharma Antibody Drug Conjugates (ADCs) Product Portfolio Table 50. Astellas Pharma Recent Development Table 51. Genmab Company Information Table 52. Genmab Business Overview Table 53. Genmab Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Genmab Antibody Drug Conjugates (ADCs) Product Portfolio Table 55. Genmab Recent Development Table 56. Kairos Therapeutics Company Information Table 57. Kairos Therapeutics Business Overview Table 58. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio Table 60. Kairos Therapeutics Recent Development Table 61. Seattle Genetics Company Information Table 62. Seattle Genetics Business Overview Table 63. Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Seattle Genetics Antibody Drug Conjugates (ADCs) Product Portfolio Table 65. Seattle Genetics Recent Development Table 66. Takeda Pharmaceuticals Company Information Table 67. Takeda Pharmaceuticals Business Overview Table 68. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product Portfolio Table 70. Takeda Pharmaceuticals Recent Development Table 71. AbbVie Company Information Table 72. AbbVie Business Overview Table 73. AbbVie Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. AbbVie Antibody Drug Conjugates (ADCs) Product Portfolio Table 75. AbbVie Recent Development Table 76. Bayer Company Information Table 77. Bayer Business Overview Table 78. Bayer Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Bayer Antibody Drug Conjugates (ADCs) Product Portfolio Table 80. Bayer Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Pfizer Antibody Drug Conjugates (ADCs) Product Portfolio Table 85. Pfizer Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche Antibody Drug Conjugates (ADCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Roche Antibody Drug Conjugates (ADCs) Product Portfolio Table 90. Roche Recent Development Table 91. Novartis Company Information Table 92. Novartis Business Overview Table 93. Novartis Antibody Drug Conjugates (ADCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Novartis Antibody Drug Conjugates (ADCs) Product Portfolio Table 95. Novartis Recent Development Table 96. North America Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026) & (US$ Million) Table 97. North America Antibody Drug Conjugates (ADCs) Revenue by Type (2027-2032) & (US$ Million) Table 98. North America Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026) & (US$ Million) Table 99. North America Antibody Drug Conjugates (ADCs) Revenue by Application (2027-2032) & (US$ Million) Table 100. North America Antibody Drug Conjugates (ADCs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Antibody Drug Conjugates (ADCs) Revenue by Country (2021-2026) & (US$ Million) Table 102. North America Antibody Drug Conjugates (ADCs) Revenue by Country (US$ Million) & (2027-2032) Table 103. Europe Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026) & (US$ Million) Table 104. Europe Antibody Drug Conjugates (ADCs) Revenue by Type (2027-2032) & (US$ Million) Table 105. Europe Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Antibody Drug Conjugates (ADCs) Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Antibody Drug Conjugates (ADCs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Antibody Drug Conjugates (ADCs) Revenue by Country (2021-2026) & (US$ Million) Table 109. Europe Antibody Drug Conjugates (ADCs) Revenue by Country (US$ Million) & (2027-2032) Table 110. China Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026) & (US$ Million) Table 111. China Antibody Drug Conjugates (ADCs) Revenue by Type (2027-2032) & (US$ Million) Table 112. China Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026) & (US$ Million) Table 113. China Antibody Drug Conjugates (ADCs) Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026) & (US$ Million) Table 115. Asia Antibody Drug Conjugates (ADCs) Revenue by Type (2027-2032) & (US$ Million) Table 116. Asia Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026) & (US$ Million) Table 117. Asia Antibody Drug Conjugates (ADCs) Revenue by Application (2027-2032) & (US$ Million) Table 118. Asia Antibody Drug Conjugates (ADCs) Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Antibody Drug Conjugates (ADCs) Revenue by Region (US$ Million) & (2021-2026) Table 120. Asia Antibody Drug Conjugates (ADCs) Revenue by Region (US$ Million) & (2027-2032) Table 121. SAMEA Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026) & (US$ Million) Table 122. SAMEA Antibody Drug Conjugates (ADCs) Revenue by Type (2027-2032) & (US$ Million) Table 123. SAMEA Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026) & (US$ Million) Table 124. SAMEA Antibody Drug Conjugates (ADCs) Revenue by Application (2027-2032) & (US$ Million) Table 125. SAMEA Antibody Drug Conjugates (ADCs) Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. SAMEA Antibody Drug Conjugates (ADCs) Revenue by Country (2021-2026) & (US$ Million) Table 127. SAMEA Antibody Drug Conjugates (ADCs) Revenue by Country (US$ Million) & (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Antibody Drug Conjugates (ADCs) Image Figure 2. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antibody Drug Conjugates (ADCs) Market Size Share 2021 VS 2025 VS 2032 Figure 4. Seattle Genetics Technology Image Figure 5. Immunomedics Technology Image Figure 6. ImmunoGen Technology Image Figure 7. Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Antibody Drug Conjugates (ADCs) Market Size Share 2021 VS 2025 VS 2032 Figure 9. Hospital Image Figure 10. Clinics Image Figure 11. Others Image Figure 12. Global Antibody Drug Conjugates (ADCs) Market Size (US$ Million) & (2021-2032) Figure 13. Global Antibody Drug Conjugates (ADCs) Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Antibody Drug Conjugates (ADCs) Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Antibody Drug Conjugates (ADCs) Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Antibody Drug Conjugates (ADCs) Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Antibody Drug Conjugates (ADCs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2021-2032) Figure 20. Global Antibody Drug Conjugates (ADCs) Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2021-2032) Figure 23. North America Antibody Drug Conjugates (ADCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Antibody Drug Conjugates (ADCs) Revenue Share by Type (2021-2032) Figure 25. North America Antibody Drug Conjugates (ADCs) Revenue Share by Application (2021-2032) Figure 26. North America Antibody Drug Conjugates (ADCs) Revenue Share by Country (2021-2032) Figure 27. United States Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Antibody Drug Conjugates (ADCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Antibody Drug Conjugates (ADCs) Revenue Share by Type (2021-2032) Figure 32. Europe Antibody Drug Conjugates (ADCs) Revenue Share by Application (2021-2032) Figure 33. Europe Antibody Drug Conjugates (ADCs) Revenue Share by Country (2021-2032) Figure 34. Germany Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Antibody Drug Conjugates (ADCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Antibody Drug Conjugates (ADCs) Revenue Share by Type (2021-2032) Figure 44. China Antibody Drug Conjugates (ADCs) Revenue Share by Application (2021-2032) Figure 45. Asia Antibody Drug Conjugates (ADCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Antibody Drug Conjugates (ADCs) Revenue Share by Type (2021-2032) Figure 47. Asia Antibody Drug Conjugates (ADCs) Revenue Share by Application (2021-2032) Figure 48. Asia Antibody Drug Conjugates (ADCs) Revenue Share by Region (2021-2032) Figure 49. Japan Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Antibody Drug Conjugates (ADCs) Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Antibody Drug Conjugates (ADCs) Revenue Share by Type (2021-2032) Figure 57. SAMEA Antibody Drug Conjugates (ADCs) Revenue Share by Application (2021-2032) Figure 58. SAMEA Antibody Drug Conjugates (ADCs) Revenue Share by Country (2021-2032) Figure 59. Brazil Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Antibody Drug Conjugates (ADCs) Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Seattle Genetics Technology
  • Immunomedics Technology
  • ImmunoGen Technology
Applications
  • Hospital
  • Clinics
  • Others
Companies covered
  • AbGenomics
  • ADC Therapeutics
  • Astellas Pharma
  • Genmab
  • Kairos Therapeutics
  • Seattle Genetics
  • Takeda Pharmaceuticals
  • AbbVie
  • Bayer
  • Pfizer
  • Roche
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Antibody Drug Conjugates (ADCs) Market by Type
  3. 1.2.1 Global Antibody Drug Conjugates (ADCs) Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Seattle Genetics Technology
  5. 1.2.3 Immunomedics Technology
  6. 1.2.4 ImmunoGen Technology
  7. 1.3 Antibody Drug Conjugates (ADCs) Market by Application
  8. 1.3.1 Global Antibody Drug Conjugates (ADCs) Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Hospital
  10. 1.3.3 Clinics
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Antibody Drug Conjugates (ADCs) Market Dynamics
  1. 2.1 Antibody Drug Conjugates (ADCs) Industry Trends
  2. 2.2 Antibody Drug Conjugates (ADCs) Industry Drivers
  3. 2.3 Antibody Drug Conjugates (ADCs) Industry Opportunities and Challenges
  4. 2.4 Antibody Drug Conjugates (ADCs) Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Antibody Drug Conjugates (ADCs) Market Perspective (2021-2032)
  2. 3.2 Global Antibody Drug Conjugates (ADCs) Growth Trends by Region
  3. 3.2.1 Global Antibody Drug Conjugates (ADCs) Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Antibody Drug Conjugates (ADCs) Market Size by Region (2021-2026)
  5. 3.2.3 Global Antibody Drug Conjugates (ADCs) Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Antibody Drug Conjugates (ADCs) Revenue by Players
  2. 4.1.1 Global Antibody Drug Conjugates (ADCs) Revenue by Players (2021-2026)
  3. 4.1.2 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Antibody Drug Conjugates (ADCs) Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Antibody Drug Conjugates (ADCs) Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Antibody Drug Conjugates (ADCs) Key Players Headquarters & Area Served
  7. 4.4 Global Antibody Drug Conjugates (ADCs) Players, Product Type & Application
  8. 4.5 Global Antibody Drug Conjugates (ADCs) Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Antibody Drug Conjugates (ADCs) Market CR5 and HHI
  11. 4.6.3 2025 Antibody Drug Conjugates (ADCs) Tier 1, Tier 2, and Tier 3
5 Antibody Drug Conjugates (ADCs) Market Size by Type
  1. 5.1 Global Antibody Drug Conjugates (ADCs) Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2032)
  3. 5.3 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type (2021-2032)
6 Antibody Drug Conjugates (ADCs) Market Size by Application
  1. 6.1 Global Antibody Drug Conjugates (ADCs) Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2032)
  3. 6.3 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AbGenomics
  2. 7.1.1 AbGenomics Company Information
  3. 7.1.2 AbGenomics Business Overview
  4. 7.1.3 AbGenomics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AbGenomics Antibody Drug Conjugates (ADCs) Product Portfolio
  6. 7.1.5 AbGenomics Recent Developments
  7. 7.2 ADC Therapeutics
  8. 7.2.1 ADC Therapeutics Company Information
  9. 7.2.2 ADC Therapeutics Business Overview
  10. 7.2.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  11. 7.2.4 ADC Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio
  12. 7.2.5 ADC Therapeutics Recent Developments
  13. 7.3 Astellas Pharma
  14. 7.3.1 Astellas Pharma Company Information
  15. 7.3.2 Astellas Pharma Business Overview
  16. 7.3.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Astellas Pharma Antibody Drug Conjugates (ADCs) Product Portfolio
  18. 7.3.5 Astellas Pharma Recent Developments
  19. 7.4 Genmab
  20. 7.4.1 Genmab Company Information
  21. 7.4.2 Genmab Business Overview
  22. 7.4.3 Genmab Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Genmab Antibody Drug Conjugates (ADCs) Product Portfolio
  24. 7.4.5 Genmab Recent Developments
  25. 7.5 Kairos Therapeutics
  26. 7.5.1 Kairos Therapeutics Company Information
  27. 7.5.2 Kairos Therapeutics Business Overview
  28. 7.5.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product Portfolio
  30. 7.5.5 Kairos Therapeutics Recent Developments
  31. 7.6 Seattle Genetics
  32. 7.6.1 Seattle Genetics Company Information
  33. 7.6.2 Seattle Genetics Business Overview
  34. 7.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Seattle Genetics Antibody Drug Conjugates (ADCs) Product Portfolio
  36. 7.6.5 Seattle Genetics Recent Developments
  37. 7.7 Takeda Pharmaceuticals
  38. 7.7.1 Takeda Pharmaceuticals Company Information
  39. 7.7.2 Takeda Pharmaceuticals Business Overview
  40. 7.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product Portfolio
  42. 7.7.5 Takeda Pharmaceuticals Recent Developments
  43. 7.8 AbbVie
  44. 7.8.1 AbbVie Company Information
  45. 7.8.2 AbbVie Business Overview
  46. 7.8.3 AbbVie Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  47. 7.8.4 AbbVie Antibody Drug Conjugates (ADCs) Product Portfolio
  48. 7.8.5 AbbVie Recent Developments
  49. 7.9 Bayer
  50. 7.9.1 Bayer Company Information
  51. 7.9.2 Bayer Business Overview
  52. 7.9.3 Bayer Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bayer Antibody Drug Conjugates (ADCs) Product Portfolio
  54. 7.9.5 Bayer Recent Developments
  55. 7.10 Pfizer
  56. 7.10.1 Pfizer Company Information
  57. 7.10.2 Pfizer Business Overview
  58. 7.10.3 Pfizer Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Pfizer Antibody Drug Conjugates (ADCs) Product Portfolio
  60. 7.10.5 Pfizer Recent Developments
  61. 7.11 Roche
  62. 7.11.1 Roche Company Information
  63. 7.11.2 Roche Business Overview
  64. 7.11.3 Roche Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Roche Antibody Drug Conjugates (ADCs) Product Portfolio
  66. 7.11.5 Roche Recent Developments
  67. 7.12 Novartis
  68. 7.12.1 Novartis Company Information
  69. 7.12.2 Novartis Business Overview
  70. 7.12.3 Novartis Antibody Drug Conjugates (ADCs) Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Novartis Antibody Drug Conjugates (ADCs) Product Portfolio
  72. 7.12.5 Novartis Recent Developments
8 North America
  1. 8.1 North America Antibody Drug Conjugates (ADCs) Revenue (2021-2032)
  2. 8.2 North America Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2032)
  3. 8.2.1 North America Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026)
  4. 8.2.2 North America Antibody Drug Conjugates (ADCs) Revenue by Type (2027-2032)
  5. 8.3 North America Antibody Drug Conjugates (ADCs) Revenue Share by Type (2021-2032)
  6. 8.4 North America Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2032)
  7. 8.4.1 North America Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026)
  8. 8.4.2 North America Antibody Drug Conjugates (ADCs) Revenue by Application (2027-2032)
  9. 8.5 North America Antibody Drug Conjugates (ADCs) Revenue Share by Application (2021-2032)
  10. 8.6 North America Antibody Drug Conjugates (ADCs) Revenue by Country
  11. 8.6.1 North America Antibody Drug Conjugates (ADCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Antibody Drug Conjugates (ADCs) Revenue by Country (2021-2026)
  13. 8.6.3 North America Antibody Drug Conjugates (ADCs) Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Antibody Drug Conjugates (ADCs) Revenue (2021-2032)
  2. 9.2 Europe Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2032)
  3. 9.2.1 Europe Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026)
  4. 9.2.2 Europe Antibody Drug Conjugates (ADCs) Revenue by Type (2027-2032)
  5. 9.3 Europe Antibody Drug Conjugates (ADCs) Revenue Share by Type (2021-2032)
  6. 9.4 Europe Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2032)
  7. 9.4.1 Europe Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026)
  8. 9.4.2 Europe Antibody Drug Conjugates (ADCs) Revenue by Application (2027-2032)
  9. 9.5 Europe Antibody Drug Conjugates (ADCs) Revenue Share by Application (2021-2032)
  10. 9.6 Europe Antibody Drug Conjugates (ADCs) Revenue by Country
  11. 9.6.1 Europe Antibody Drug Conjugates (ADCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Antibody Drug Conjugates (ADCs) Revenue by Country (2021-2026)
  13. 9.6.3 Europe Antibody Drug Conjugates (ADCs) Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Antibody Drug Conjugates (ADCs) Revenue (2021-2032)
  2. 10.2 China Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2032)
  3. 10.2.1 China Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026)
  4. 10.2.2 China Antibody Drug Conjugates (ADCs) Revenue by Type (2027-2032)
  5. 10.3 China Antibody Drug Conjugates (ADCs) Revenue Share by Type (2021-2032)
  6. 10.4 China Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2032)
  7. 10.4.1 China Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026)
  8. 10.4.2 China Antibody Drug Conjugates (ADCs) Revenue by Application (2027-2032)
  9. 10.5 China Antibody Drug Conjugates (ADCs) Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Antibody Drug Conjugates (ADCs) Revenue (2021-2032)
  2. 11.2 Asia Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2032)
  3. 11.2.1 Asia Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026)
  4. 11.2.2 Asia Antibody Drug Conjugates (ADCs) Revenue by Type (2027-2032)
  5. 11.3 Asia Antibody Drug Conjugates (ADCs) Revenue Share by Type (2021-2032)
  6. 11.4 Asia Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2032)
  7. 11.4.1 Asia Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026)
  8. 11.4.2 Asia Antibody Drug Conjugates (ADCs) Revenue by Application (2027-2032)
  9. 11.5 Asia Antibody Drug Conjugates (ADCs) Revenue Share by Application (2021-2032)
  10. 11.6 Asia Antibody Drug Conjugates (ADCs) Revenue by Country
  11. 11.6.1 Asia Antibody Drug Conjugates (ADCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Antibody Drug Conjugates (ADCs) Revenue by Country (2021-2026)
  13. 11.6.3 Asia Antibody Drug Conjugates (ADCs) Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Antibody Drug Conjugates (ADCs) Revenue (2021-2032)
  2. 12.2 SAMEA Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Antibody Drug Conjugates (ADCs) Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Antibody Drug Conjugates (ADCs) Revenue by Type (2027-2032)
  5. 12.3 SAMEA Antibody Drug Conjugates (ADCs) Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Antibody Drug Conjugates (ADCs) Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Antibody Drug Conjugates (ADCs) Revenue by Application (2027-2032)
  9. 12.5 SAMEA Antibody Drug Conjugates (ADCs) Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Antibody Drug Conjugates (ADCs) Revenue by Country
  11. 12.6.1 SAMEA Antibody Drug Conjugates (ADCs) Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Antibody Drug Conjugates (ADCs) Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Antibody Drug Conjugates (ADCs) Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst